Testing new drugs for advanced cancers with RAS gene mutations

This trial is testing two different treatment approaches for people with advanced cancers that contain a RAS gene mutation and have stopped responding to standard therapies. One approach uses a medication called leflunomide, which works by blocking a specific enzyme that helps RAS-mutated cancer cells grow. The other approach combines a MEK inhibitor with hydroxychloroquine (also known as Plaquenil), which work together to slow cancer growth through different mechanisms.

RAS gene mutations are very common in many types of advanced cancer, but they can be difficult to treat with current standard therapies. This trial exists because researchers believe these two medications may offer new hope for patients whose cancers have become resistant to existing treatments.